Trio Plans Anti-COVID-19 Vaccine Derived From Simian Adenoviruses
Comprises Italy’s ReiThera, Germany’s Leukocare, Belgium’s Univercel
Three European biotechs have joined forces to develop and manufacture a simian adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
